Pfizer Inc. (NYSE:PFE) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data On March 24, Guggenheim Partners raised its price recommendation on Pfizer Inc. (NYSE:PFE) to $36 from $35. It reiterated a Buy rating on the shares. The analyst pointed to upcoming data from the MEVPRO-1 Phase 3 trial of mevrometostat in second-line and later mCRPC, expected in the second half of 2026. Based on that setup, ...